|
| 37856781 | SLCO1B3 and SLCO2B1 genotypes, androgen deprivation therapy, and prostate cancer outcomes: a prospective cohort study and meta-analysis. | Carcinogenesis | 2024 |
| 37856781 | SLCO1B3 and SLCO2B1 genotypes, androgen deprivation therapy, and prostate cancer outcomes: a prospective cohort study and meta-analysis. | Carcinogenesis | 2024 |
| 37246339 | Experience with the US health care system for Black and White patients with advanced prostate cancer. | Cancer | 2023 |
| 37246339 | Experience with the US health care system for Black and White patients with advanced prostate cancer. | Cancer | 2023 |
| 34802033 | Prognostic and therapeutic significance of COP9 signalosome subunit CSN5 in prostate cancer. | Oncogene | 2022 |
| 35657341 | The Impact of Androgen Deprivation Therapy on COVID-19 Illness in Men With Prostate Cancer. | JNCI Cancer Spectr | 2022 |
| 36087093 | Increased MYBL2 expression in aggressive hormone-sensitive prostate cancer. | Mol Oncol | 2022 |
| 36332173 | IRONMAN: A Novel International Registry of Men With Advanced Prostate Cancer. | JCO Glob Oncol | 2022 |
| 36125434 | Differences in Prostate Cancer Transcriptomes by Age at Diagnosis: Are Primary Tumors from Older Men Inherently Different? | Cancer Prev Res (Phila) | 2022 |
| 35670774 | The Impact of PIK3R1 Mutations and Insulin-PI3K-Glycolytic Pathway Regulation in Prostate Cancer. | Clin Cancer Res | 2022 |
| 35538298 | Clinical annotations for prostate cancer research: Defining data elements, creating a reproducible analytical pipeline, and assessing data quality. | Prostate | 2022 |
| 34802033 | Prognostic and therapeutic significance of COP9 signalosome subunit CSN5 in prostate cancer. | Oncogene | 2022 |
| 34792282 | Dynamic expression of SNAI2 in prostate cancer predicts tumor progression and drug sensitivity. | Mol Oncol | 2022 |
| 35031563 | Inhibition of EZH2 transactivation function sensitizes solid tumors to genotoxic stress. | Proc Natl Acad Sci U S A | 2022 |
| 34667026 | Differences in Prostate Cancer Genomes by Self-reported Race: Contributions of Genetic Ancestry, Modifiable Cancer Risk Factors, and Clinical Factors. | Clin Cancer Res | 2022 |
| 35538298 | Clinical annotations for prostate cancer research: Defining data elements, creating a reproducible analytical pipeline, and assessing data quality. | Prostate | 2022 |
| 35670774 | The Impact of PIK3R1 Mutations and Insulin-PI3K-Glycolytic Pathway Regulation in Prostate Cancer. | Clin Cancer Res | 2022 |
| 35657341 | The Impact of Androgen Deprivation Therapy on COVID-19 Illness in Men With Prostate Cancer. | JNCI Cancer Spectr | 2022 |
| 36332173 | IRONMAN: A Novel International Registry of Men With Advanced Prostate Cancer. | JCO Glob Oncol | 2022 |
| 36125434 | Differences in Prostate Cancer Transcriptomes by Age at Diagnosis: Are Primary Tumors from Older Men Inherently Different? | Cancer Prev Res (Phila) | 2022 |
| 36087093 | Increased MYBL2 expression in aggressive hormone-sensitive prostate cancer. | Mol Oncol | 2022 |
| 35031563 | Inhibition of EZH2 transactivation function sensitizes solid tumors to genotoxic stress. | Proc Natl Acad Sci U S A | 2022 |
| 34792282 | Dynamic expression of SNAI2 in prostate cancer predicts tumor progression and drug sensitivity. | Mol Oncol | 2022 |
| 34667026 | Differences in Prostate Cancer Genomes by Self-reported Race: Contributions of Genetic Ancestry, Modifiable Cancer Risk Factors, and Clinical Factors. | Clin Cancer Res | 2022 |
| 32997608 | Benchmarks for Academic Oncology Faculty. | JCO Oncol Pract | 2021 |
| 33734288 | Effectiveness of Electroacupuncture or Auricular Acupuncture vs Usual Care for Chronic Musculoskeletal Pain Among Cancer Survivors: The PEACE Randomized Clinical Trial. | JAMA Oncol | 2021 |
| 33835826 | Tackling Diversity in Prostate Cancer Clinical Trials: A Report From the Diversity Working Group of the IRONMAN Registry. | JCO Glob Oncol | 2021 |
| 33823065 | Prostate-specific antigen nadir and testosterone level at prostate-specific antigen failure following radiation and androgen suppression therapy for unfavorable-risk prostate cancer and the risk of all-cause and prostate cancer-specific mortality. | Cancer | 2021 |
| 33495313 | Abiraterone Acetate Induces CREB1 Phosphorylation and Enhances the Function of the CBP-p300 Complex, Leading to Resistance in Prostate Cancer Cells. | Clin Cancer Res | 2021 |
| 32857839 | Inferences About Drug Safety in Phase III Trials in Oncology: Examples From Advanced Prostate Cancer. | J Natl Cancer Inst | 2021 |
| 33334906 | Attenuation of SRC Kinase Activity Augments PARP Inhibitor-mediated Synthetic Lethality in <i>BRCA2</i>-altered Prostate Tumors. | Clin Cancer Res | 2021 |
| 32997608 | Benchmarks for Academic Oncology Faculty. | JCO Oncol Pract | 2021 |
| 34407973 | Circulating and Intratumoral Adrenal Androgens Correlate with Response to Abiraterone in Men with Castration-Resistant Prostate Cancer. | Clin Cancer Res | 2021 |
| 34685549 | Evaluation of an RNAseq-Based Immunogenomic Liquid Biopsy Approach in Early-Stage Prostate Cancer. | Cells | 2021 |
| 34551377 | Novel genomic signature predictive of response to immune checkpoint blockade: A pan-cancer analysis from project Genomics Evidence Neo-plasia Information Exchange (GENIE). | Cancer Genet | 2021 |
| 34939926 | Extent, impact, and mitigation of batch effects in tumor biomarker studies using tissue microarrays. | Elife | 2021 |
| 34533974 | Reply to G. Francolini et al. | J Clin Oncol | 2021 |
| 33495313 | Abiraterone Acetate Induces CREB1 Phosphorylation and Enhances the Function of the CBP-p300 Complex, Leading to Resistance in Prostate Cancer Cells. | Clin Cancer Res | 2021 |
| 33823065 | Prostate-specific antigen nadir and testosterone level at prostate-specific antigen failure following radiation and androgen suppression therapy for unfavorable-risk prostate cancer and the risk of all-cause and prostate cancer-specific mortality. | Cancer | 2021 |
| 33734288 | Effectiveness of Electroacupuncture or Auricular Acupuncture vs Usual Care for Chronic Musculoskeletal Pain Among Cancer Survivors: The PEACE Randomized Clinical Trial. | JAMA Oncol | 2021 |
| 33835826 | Tackling Diversity in Prostate Cancer Clinical Trials: A Report From the Diversity Working Group of the IRONMAN Registry. | JCO Glob Oncol | 2021 |
| 34939926 | Extent, impact, and mitigation of batch effects in tumor biomarker studies using tissue microarrays. | Elife | 2021 |
| 34407973 | Circulating and Intratumoral Adrenal Androgens Correlate with Response to Abiraterone in Men with Castration-Resistant Prostate Cancer. | Clin Cancer Res | 2021 |
| 34551377 | Novel genomic signature predictive of response to immune checkpoint blockade: A pan-cancer analysis from project Genomics Evidence Neo-plasia Information Exchange (GENIE). | Cancer Genet | 2021 |
| 34685549 | Evaluation of an RNAseq-Based Immunogenomic Liquid Biopsy Approach in Early-Stage Prostate Cancer. | Cells | 2021 |
| 34533974 | Reply to G. Francolini et al. | J Clin Oncol | 2021 |
| 33334906 | Attenuation of SRC Kinase Activity Augments PARP Inhibitor-mediated Synthetic Lethality in <i>BRCA2</i>-altered Prostate Tumors. | Clin Cancer Res | 2021 |
| 32857839 | Inferences About Drug Safety in Phase III Trials in Oncology: Examples From Advanced Prostate Cancer. | J Natl Cancer Inst | 2021 |
| 31420248 | Mortality and Hospitalization Risk Following Oral Androgen Signaling Inhibitors Among Men with Advanced Prostate Cancer by Pre-existing Cardiovascular Comorbidities. | Eur Urol | 2020 |
| 32198083 | Patterns of self-reported care in a cohort of prostate cancer survivors: Implications for risk-stratified care. | J Geriatr Oncol | 2020 |